Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol-free and low-alcohol products in higher risk groups.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol-free and low-alcohol products in higher risk groups.
Συγγραφείς:	Holmes J; School of Medicine and Population Health, University of Sheffield, Sheffield, UK., Oldroyd CK; National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, Cambridge, UK.; Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Drummond C; National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK., Field M; School of Psychology, University of Sheffield, Interdisciplinary Centre of the Social Sciences (ICOSS) Building, Sheffield, UK., Kersbergen I; School of Medicine and Population Health, University of Sheffield, Sheffield, UK., Allison MED; National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, Cambridge, UK.; Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Πηγή:	Addiction (Abingdon, England) [Addiction] 2026 May; Vol. 121 (5), pp. 1036-1041. Date of Electronic Publication: 2025 Nov 09.
Τύπος έκδοσης:	Journal Article; Review
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9304118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1360-0443 (Electronic) Linking ISSN: 09652140 NLM ISO Abbreviation: Addiction Subsets: MEDLINE
Imprint Name(s):	Publication: Oxford : Wiley-Blackwell Original Publication: Abingdon, Oxfordshire, UK : Carfax Pub. Co., c1993-
Ιατρικοί όροι (MeSH):	Alcohol Drinking/prevention & control , Alcoholism/prevention & control , Alcohol-Related Disorders/prevention & control , Alcoholic Beverages, Humans ; Alcohol Abstinence
Περίληψη:	Alcohol-free and low-alcohol drinks (no/lo drinks) are now widely available and popular with consumers in high-income countries; however, it is unclear whether clinicians and others working to prevent or treat severe alcohol-related health problems should take a zero-tolerance approach to these alcohol-like products or encourage patients to try them. We argue that no/lo drinks may have an important role to play for people who drink at high-risk levels and those with alcohol use disorders (AUD) or alcohol-related liver disease (ARLD), particularly where debate and guidance related to treatment of these problems considers goals other than abstinence. The limited available evidence available suggests no/lo drinks may be useful in supporting attempts to reduce alcohol consumption or maintain abstinence among high-risk drinkers who do not have severe AUD or ARLD; however, they may also entail significant risks of relapse in those recovering from AUD. We therefore need further experimental and longitudinal studies testing whether use of no/lo drinks can lead to, or support, reductions in alcohol consumption. We particularly need high-quality experimental studies to test whether exposure to and sustained use of no/lo drinks affects treatment and recovery outcomes. Evidence is also needed on which subgroups of AUD and ARLD patients would benefit or be at risk from use of either alcohol-free or low-alcohol drinks. Finally, guidance should recognise that many patients already use these products and that a zero-tolerance approach may alienate patients or erode trust in clinicians. (© 2025 The Author(s). Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.)
References:	World Health Organization. A public health perspective on zero‐ and low‐alcohol beverages Geneva: World Health Organization; 2023. Miller M, Pettigrew S, Wright CJ. Zero‐alcohol beverages: Harm‐minimisation tool or gateway drink? Drug Alcohol Rev. 2022;41(3):546–549. https://doi.org/10.1111/dar.13359. Corfe S, Hyde R, Shepherd J. Alcohol‐free and low‐strength drinks: understanding their role in reducing alcohol‐related harms London: Social Market Foundation; 2020. Hew A, Arunogiri S. Zero alcohol, but not zero risk?: SAGE publications London, England: Sage UK; 2024. p. 10–11. Caballeria E, Pons‐Cabrera MT, Balcells‐Oliveró M, Braddick F, Gordon R, Gual A, et al. “Doctor, can I drink an alcohol‐free beer?”; Low‐Alcohol and Alcohol‐Free Drinks in People with Heavy Drinking or Alcohol Use Disorders: Systematic Review of the Literature. Nutrients. 2022;14(19):3925. https://doi.org/10.3390/nu14193925. Holmes J, Angus C, Kersbergen I, Pryce R, Stevely A, Wilson L. No‐ and low‐alcohol drinks in Great Britain: Monitoring report update to end of 2023 Sheffield: University of Sheffield; Forthcoming https://sarg-sheffield.ac.uk/wp-content/uploads/2024/01/SARGNoLoMonitoringReportJan24.pdf Accessed 4 Feb 2024. Schuckit MA. Alcohol‐use disorders. Lancet. 2009;373(9662):492–501. https://doi.org/10.1016/S0140-6736(09)60009-X. Edwards G, Gross MM. Alcohol dependence: provisional description of a clinical syndrome. BMJ. 1976;1(6017):1058–1061. https://doi.org/10.1136/bmj.1.6017.1058. Hofer BS, Simbrunner B, Hartl L, Jachs M, Bauer DJM, Balcar L, et al. Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol‐related cirrhosis. Clin Gastroenterol Hepatol. 2023;21:2308–2317.e2307. Lim WH, Tay P, Ng CH, Tan DJH, Ong C, Koh JH, et al. Meta‐analysis: prevalence and impact of alcohol abstinence in alcohol‐associated cirrhosis. Aliment Pharmacol Ther. 2024;59(6):730–741. https://doi.org/10.1111/apt.17888. Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619–1628. https://doi.org/10.1056/NEJMoa1412278. Witkiewitz K, Kranzler HR, Hallgren KA, Hasin DS, Aldridge AP, Zarkin GA, et al. Stability of drinking reductions and long‐term functioning among patients with alcohol use disorder. J Gen Intern Med. 2021;36(2):404–412. https://doi.org/10.1007/s11606-020-06331-x. Hagman BT, Falk D, Litten R, Koob GF. Defining recovery from alcohol use disorder: development of an NIAAA research definition. Am J Psychiatry. 2022;179(11):807–813. https://doi.org/10.1176/appi.ajp.21090963. Henssler J, Müller M, Carreira H, Bschor T, Heinz A, Baethge C. Controlled drinking—non‐abstinent versus abstinent treatment goals in alcohol use disorder: a systematic review, meta‐analysis and meta‐regression. Addiction. 2021;116(8):1973–1987. https://doi.org/10.1111/add.15329. Singal AK, Kwo P, Kwong A, Liangpunsakul S, Louvet A, Mandrekar P, et al. Research methodologies to address clinical unmet needs and challenges in alcohol‐associated liver disease. Hepatology. 2022;75(4):1026–1037. https://doi.org/10.1002/hep.32143. Witkiewitz K, Anton RF, O'Malley SS, Hasin DS, Silverman BL, Aldridge A, et al. Reductions in World Health Organization risk drinking levels as a primary efficacy end point for alcohol clinical trials: A review. JAMA Psychiatr. 2025. National Institute for health and care excellence. Alcohol‐use disorders: the NICE guideline on diagnosis, assessment and Management of Harmful Drinking and Alcohol Dependence. Clinical guideline 115 London: NICE; 2011. World Health Organization. MhGAP intervention guide: version 2, for mental, neurological and substance use disorder in non‐specialized health settings Geneva: World Health Organization; 2016 https://www.who.int/publications/i/item/9789241549790 Accessed 20 Oct 2024. Center for Drug Evaluation and Research. Alcoholism: Developing Drugs for Treatment U.S. Food and Drug Administration; 2015 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alcoholism-developing-drugs-treatment Accessed 20 Oct 2024. European Medicines Agency. Annual Report 2010 (adopted by the management board June 28, 2011). EMA/306870/2011 Amsterdam: EMA; 2011 https://www.ema.europa.eu/en/documents/annual-report/annual-report-european-medicines-agency-2011_en.pdf Accessed 20 Oct 2024. Kaner EF, Beyer FR, Muirhead C, Campbell F, Pienaar ED, Bertholet N, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2018; 2(2):CD004148. Magwood O, Salvalaggio G, Beder M, Kendall C, Kpade V, Daghmach W, et al. The effectiveness of substance use interventions for homeless and vulnerably housed persons: a systematic review of systematic reviews on supervised consumption facilities, managed alcohol programs, and pharmacological agents for opioid use disorder. PLoS ONE. 2020;15(1):e0227298. https://doi.org/10.1371/journal.pone.0227298. Anderson P, O'Donnell A, Jané Llopis E, Kaner E. The impact of lower strength alcohol products on alcohol purchases: ARIMA analyses based on 4 million purchases by 69 803 households, 2015–2019. J Public Health. 2022;44(4):e567–e577. https://doi.org/10.1093/pubmed/fdac052. Perman‐Howe PR, Holmes J, Brown J, Kersbergen I. Characteristics of consumers of alcohol‐free and low‐alcohol drinks in Great Britain: a cross‐sectional study. Drug Alcohol Rev. 2024;43(7):1686–1697. https://doi.org/10.1111/dar.13930. Anderson P, O'Donnell A, Kokole D, Llopis EJ, Kaner E. Is buying and drinking zero and low alcohol beer a higher socio‐economic phenomenon? Analysis of British survey data, 2015–2018 and household purchase data 2015–2020. Int J Environ Res Public Health. 2021;18:10347. Katainen A, Uusitalo L, Saarijärvi H, Erkkola M, Rahkonen O, Lintonen T, et al. Who buys non‐alcoholic beer in Finland? Sociodemographic characteristics and associations with regular beer purchases. Int J Drug Policy. 2023;113:103962. https://doi.org/10.1016/j.drugpo.2023.103962. Perman‐Howe PR, Davies EL, Foxcroft DR. The effect of alcohol strength on alcohol consumption: a randomised controlled cross‐over pilot trial. Pilot Feasib Stud. 2018;4(1):138. https://doi.org/10.1186/s40814-018-0328-y. Davey C. It's kind of like weaning. I had to wean myself off of wine’: Navigating no‐ and low‐alcohol drinks as potential harm reduction tools and relapse triggers by women in recovery in the UK. Drug Alcohol Rev. 2024; 43(1):156–164. Nicholls E. Not just living in the moment’: constructing the ‘enterprising'and future‐oriented self through the consumption of no‐and‐low‐alcohol drinks. Sociol Res Online. 2023;29(3):13607804231191063. https://doi.org/10.1177/13607804231191063. Critchlow N, Holmes J, Fitzgerald N. Alibi marketing? Surrogate marketing? Brand sharing? What is the correct terminology to discuss marketing for alcohol‐free and low‐alcohol products which share branding with regular strength alcohol products? Addiction. 2025; 120(1):4–6. Drummond DC. Theories of drug craving, ancient and modern. Addiction. 2001;96(1):33–46. https://doi.org/10.1046/j.1360-0443.2001.961333.x. Hodgson R, Rankin H, Stockwell T. Alcohol dependence and the priming effect. Behav Res Ther. 1979;17(4):379–387. https://doi.org/10.1016/0005-7967(79)90009-3. Stockwell T, Hodgson R, Rankin H, Taylor C. Alcohol dependence, beliefs and the priming effect. Behav Res Ther. 1982;20(5):513–522. https://doi.org/10.1016/0005-7967(82)90072-9. Rose AK, Hobbs M, Drummond C. Differentiating the contribution of pharmacological from alcohol expectancy effects to changes in subjective response and priming over successive drinks. Alcohol Clin Exp Res. 2013;37(4):687–695. https://doi.org/10.1111/acer.12022. Dolinsky ZS, Morse DE, Kaplan RF, Meyer RE, Corry D, Pomerleau OF. Neuroendocrine, psychophysiological and subjective reactivity to an alcohol placebo in male alcoholic patients. Alcohol Clin Exp Res. 1987;11(3):296–300. https://doi.org/10.1111/j.1530-0277.1987.tb01311.x. Kaplan RF, Meyer RE, Stroebel CF. Alcohol dependence and responsivity to an ethanol stimulus as predictors of alcohol consumption. Br J Addict. 1983;78(3):259–267. https://doi.org/10.1111/j.1360-0443.1983.tb02510.x. Waddell JT, King SE, Corbin WR. Disentangling between‐and within‐person alcohol and expectancy effects on acute alcohol craving. Psychopharmacology (Berl). 2023;240(6):1333–1342. https://doi.org/10.1007/s00213-023-06372-0. Bainbridge L. Transferring 24/7 sobriety from South Dakota to South London: the case of MOPAC'S alcohol abstinence monitoring requirement pilot. Addiction. 2019;114(9):1696–1705. https://doi.org/10.1111/add.14609. Macías‐Rodríguez RU, Ruiz‐Margáin A, Román‐Calleja BM, Espin‐Nasser ME, Flores‐García NC, Torre A, et al. Effect of non‐alcoholic beer, diet and exercise on endothelial function, nutrition and quality of life in patients with cirrhosis. World J Hepatol. 2020;12(12):1299–1313. https://doi.org/10.4254/wjh.v12.i12.1299. Altamirano J, Bataller R, Cardenas A, Michelena J, Freixa N, Monrás M, et al. Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease. Ann Hepatol. 2012;11(2):213–221. https://doi.org/10.1016/S1665-2681(19)31026-9. Banister E, Piacentini MG, Grimes A. Identity refusal: distancing from non‐drinking in a drinking culture. Sociology. 2019;53(4):744–761. https://doi.org/10.1177/0038038518818761. Thursz M, Gual A, Lackner C, Mathurin P, Moreno C, Spahr L, et al. EASL clinical practice guidelines: management of alcohol‐related liver disease. J Hepatol. 2018;69(1):154–181. https://doi.org/10.1016/j.jhep.2018.03.018. Masson S, Aldersley H, Leithead JA, Day E, Langford A, Healy P, et al. Liver transplantation for alcohol‐related liver disease in the UK: revised UK liver advisory group recommendations for referral. Lancet Gastroenterol Hepatol. 2021;6(11):947–955. https://doi.org/10.1016/S2468-1253(21)00195-3. Parker R, Allison M, Anderson S, Aspinall R, Bardell S, Bains V, et al. Quality standards for the management of alcohol‐related liver disease: consensus recommendations from the British Association for the Study of the liver and British Society of Gastroenterology ARLD special interest group. BMJ Open Gastroenterol. 2023;10(1):e001221. https://doi.org/10.1136/bmjgast-2023-001221. Jophlin LL, Singal AK, Bataller R, Wong RJ, Sauer BG, Terrault NA, et al. ACG clinical guideline: alcohol‐associated liver disease. Off J Am College Gastroenterol ACG. 2024;119:30–54. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol‐associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306–333. https://doi.org/10.1002/hep.30866. Mansour D, Masson S, Hammond J, Leithead JA, Johnson J, Rahim MN, et al. British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis–part 3: special circumstances. Frontl Gastroenterol. 2023;14(6):474–482. https://doi.org/10.1136/flgastro-2023-102432. National Institute for health and care excellence. Cirrhosis in over 16s: assessment and management London: NICE; 2016. Bowdring MA, Rutledge GW, Prochaska JJ. Advising patients on the use of non‐alcoholic beverages that mirror alcohol. Prev Med Rep. 2024;47:102888. https://doi.org/10.1016/j.pmedr.2024.102888. Mellinger JL, Winder GS, Fernandez AC, Asefah H, Zikmund‐Fisher BJ. Critical misconceptions and knowledge gaps regarding alcohol cessation and risk of relapse in alcohol‐related liver disease patients: a qualitative mental models study. J Subst Use Addict Treatm. 2024;161:209292. https://doi.org/10.1016/j.josat.2024.209292. Thierauf A, Gnann H, Wohlfarth A, Auwärter V, Perdekamp MG, Buttler K‐J, et al. Urine tested positive for ethyl glucuronide and ethyl sulphate after the consumption of “non‐alcoholic” beer. Forensic Sci Int. 2010;202(1‐3):82–85. https://doi.org/10.1016/j.forsciint.2010.04.031.
Grant Information:	NIHR302571 National Institute for Health and Care Research; National Institute for Health Research Applied Research Collaboration South London; NIHR135310 Public Health Research Programme; NIHR Maudsley Biomedical Research Centre
Contributed Indexing:	Keywords: alcohol dependence; alcohol policy; clinical guidelines; harmful drinking; hazardous drinking; liver cirrhosis; non‐alcoholic; treatment guidelines; zero alcohol
Entry Date(s):	Date Created: 20251110 Date Completed: 20260417 Latest Revision: 20260419
Update Code:	20260419
PubMed Central ID:	PMC13088919
DOI:	10.1111/add.70244
PMID:	41208345
Βάση Δεδομένων:	MEDLINE

Περιγραφή
ISSN:	1360-0443
DOI:	10.1111/add.70244